tbuckley/cabot-search huggingface dataset:
Causes of Induction Failure in Newly Diagnosed Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Idarubicin (AIDA).
Authors: Javier de la Serna, Guillermo Martin, Edo Vellenga, Chelo Rayon, Concha Rivas, Guillermo Deben, Marcos Gonzalez, Mar Tormo, Juan Bergua, Jaoquin Diaz-Mediavilla, Angel Leon, Jordi Esteve, Ricardo Parody, Elena Amutio, Jose D. Gonzalez, Silvia Negri, Francisco J. Capote, Javier Bueno, Manuel Perez-Encina, Andres Novo, Antonia Rodriguez, Miguel A. Sanz
Journal: Blood (2004)
Zap-70 on Bone Marrow Biopsy Is a Good Prognostic Indicator in B-CLL.
Authors: Giorgio Lambertenghi Deliliers, Claudia Vener, Umberto Gianelli, Silvano Bosari, Federica Savi, Agostino Cortelezzi, Franco Somalvico, Davide Soligo, Nicola S. Fracchiolla
Journal: Blood (2004)
Rituximab for Treatment of Resistant Inhibitors in Severe Haemophilia a: A Consecutive National Cohort.
Authors: Raina Liesner, Mary Mathias, John Hanley, Russell Keenan, David M. Keeling, Michael Laffan, Elizabeth Chalmers, Charles R.M. Hay, Rhona Maclean, Savita Rangarajan, Mike Williams, David J. Perry, Peter Collins
Journal: Blood (2008)
Functional Consequences of Genetic Variation across the Entire MBL2 Locus: Possible Identification of 3′ SNPs That Could Modify Circulating Levels of MBL.
Authors: Toralf Bernig, Willemijn Breunis, Nannette Brouwer, Dirk Roos, Taco W. Kuijpers, Stephen J. Chanock
Journal: Blood (2004)
Murine ultrasound-guided transabdominal para-aortic injections of self-assembling type I collagen oligomers
Authors: Alexa A. Yrineo, Amelia R. Adelsperger, Abigail C. Durkes, Matthew R. Distasi, Sherry L. Voytik-Harbin, Michael P. Murphy, Craig J. Goergen
Journal: Journal of Controlled Release (2017)
The Tick Protein Ir-Cpi Efficiently Delays Contact Pathway Induced Thrombin Generation and Displays In Vivo Antithrombotic Activity
Authors: Severine Robert, Yves Decrem, Géraldine Rath, Chantal Dessy, Olivier Feron, François Mullier, Bernard Chatelain, Philippe Devel, Jean-Michel Dogné, Edmond Godfroid
Journal: Blood (2010)
Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score
Authors: Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Luatti, Gianantonio Rosti, Marilina Amabile, Angela Poerio, Ilaria Iacobucci, Simona Soverini, Thea Kalebic, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2008)
Cone Genesis Tracing by the Chrnb4-EGFP Mouse Line: Evidences of Cellular Material Fusion after Cone Precursor Transplantation
Authors: Sarah Decembrini, Catherine Martin, Florian Sennlaub, Sylvain Chemtob, Martin Biel, Marijana Samardzija, Alexandre Moulin, Francine Behar-Cohen, Yvan Arsenijevic
Journal: Molecular Therapy (2017)

The cone function is essential to mediate high visual acuity, color vision, and daylight vision. Inherited cone dystrophies and age-related macular degeneration affect a substantial percentage of the world population. To identify and isolate the most competent cells for transplantation and integration into the retina, cone tracing during development would be an important added value. To that aim, the Chrnb4-EGFP mouse line was characterized throughout retinogenesis. It revealed a sub-population of early retinal progenitors expressing the reporter gene that is progressively restricted to mature cones during retina development. The presence of the native CHRNB4 protein was confirmed in EGFP-positive cells, and it presents a similar pattern in the human retina. Sub-retinal transplantations of distinct subpopulations of Chrnb4-EGFP-expressing cells revealed the embryonic day 15.5 high-EGFP population the most efficient cells to interact with host retinas to provoke the appearance of EGFP-positive cones in the photoreceptor layer. Importantly, transplantations into the DsRed retinas revealed material exchanges between donor and host retinas, as >80% of transplanted EGFP-positive cones also were DsRed positive. Whether this cell material fusion is of significant therapeutic advantage requires further thorough investigations. The Chrnb4-EGFP mouse line definitely opens new research perspectives in cone genesis and retina repair.
Micro-RNA Expression Profiling Reveals Distinct Correlates to Disease Pathogenesis, and Identifies Novel Pathways Involved in Tumor Cell Senescence and IL-12A Signaling.
Authors: Zachary Hunter, Jenny Sun, Sophia Adamia, Yang Cao, Hsiuyi Tseng, Megan Lewicki, Lian Xu, Guang Yang, Yangsheng Zhou, Xia Liu, Ping Gong, Christina Hanzis, Thea Ioakimidis, Bryan Ciccarelli, Robert Manning, Patricia Sheehy, Christopher J Patterson, Christopher Andry, Steven Treon
Journal: Blood (2009)
Next Generation Mutational Profiling Improves Prognostication in Younger Patients with Acute Myeloid Leukemia
Authors: Caroline E Sloan, Phyllis A. Gimotty, Anne Boccuti, Alison R. Sehgal, Jianhua Zhao, Robert Daber, Jennifer JD Morrissette, Selina M. Luger, Adam Bagg, Martin P. Carroll
Journal: Blood (2014)
Suppression of Cdc37 Induces Bortezomib Resistance through Autophagy Activation and Plasma Cell Immaturation in Multiple Myeloma
Authors: Meirong Zang, Fengyan Jin, Lanting Liu, Gang An, Xiaoqi Qin, Xiaoyan Feng, Yan Xu, Mu Hao, Wen Zhou, Lugui Qiu
Journal: Blood (2015)
Failure to Recover Thymopoiesis After Allogeneic Hematopoietic Stem Cell Transplantation Predicts for High Incidence of Opportunistic Infections and Non-Relapse Mortality
Authors: Evert-Jan Wils, Bronno van der Holt, Annoek E.C. Broers, Sandra J. Posthumus-van Sluijs, Jan W. Gratama, Eric Braakman, Jan J. Cornelissen
Journal: Blood (2010)
Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study
Authors: Lars Erik Kristensen, Tanja S Jørgensen, Robin Christensen, Henrik Gudbergsen, Lene Dreyer, Christine Ballegaard, Lennart T H Jacobsson, Vibeke Strand, Philip J Mease, Jakob Kjellberg
Journal: Annals of the Rheumatic Diseases (2017)

Objectives To comprehensively study the comorbidities, healthcare and public transfer (allowance) costs in patients with psoriatic arthritis (PsA) before and after diagnosis. Methods Nationwide cohort study, using data from Danish registries from January 1998 through December 2014. A total of 10 525 patients with PsA and 20 777 matched general population comparator (GPC) subjects were included. Societal costs, employment status and occurrence of comorbidities in patients with PsA both before and after diagnosis were compared with GPC subjects. Results At baseline, patients with PsA had significantly more comorbidities, including cardiovascular disease (OR 1 . 70 95% CI 1 . 55 to 1 . 86), respiratory diseases (OR 1 . 73 95% CI 1 . 54 to 1 . 96) and infectious diseases (OR 2 . 03 95% CI 1 . 69 to 2 . 42) compared with GPC subjects. At all time points, patients with PsA had higher total healthcare and public transfer costs; they also had lower income (p&lt;0.001) and incurred a net average increased societal cost of €10 641 per patient-year compared with GPC subjects following diagnosis. The relative risk (RR) for being on disability pension 5 years prior to PsA diagnosis was 1 . 36 (95% CI 1 . 24 to 1 . 49) compared with GPC subjects. The RR increased to 1 . 60 (95% CI 1 . 49 to 1 . 72) at the time of diagnosis and was 2 . 69 (95% CI 2 . 40 to 3 . 02) 10 years after diagnosis, where 21 . 8% of the patients with PsA received disability pension. Conclusions Our findings are suggestive of health inequity for patients with PsA and call for individual preventive measures and societal action.
GPIbα Activation Triggers Platelet Tissue Factor/FVIIa-Dependent Procoagulant Activity, Which Is Dampened By Platelet Secreted TFPI and Protein S. Novel Platelet-Based Model of Hemostasis
Authors: Olga Panes, César González, Gustavo Soto, Jaime Pereira, Valeria Matus, Claudia G. Sáez, Patricia Hidalgo, Diego Mezzano
Journal: Blood (2014)
Imatinib Plasma Levels and Its Correlation with Response in Chronic-Phase Chronic Myeloid Leukemia: Experience of One Centre.
Authors: J. Valentin Garcia. Gutierrez, Jesús Odriozola, Pilar Herrera, Javier Lopez, Maria Calbacho, Marta Jimenez-Rolando, Maria Blanchard, Anabelle Chinea, Maria Tenorio, Jose García-Laraña
Journal: Blood (2009)
Effectiveness of Second Line Treatment in AL Amyloidosis Patients Refractory to M-Dex.
Authors: Julie Abraham, Houria Debarri, Amelie Penot, Estelle Desport, Claire Aguilar, Fatima Yagoubi, Xavier Leleu, Alain Goldstein, Dominique Bordessoule, Brigitte Kolb, Franck Bridoux, Jean-Paul Fermand, Veronique Leblond, Arnaud Jaccard
Journal: Blood (2009)
Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk
Authors: Anthony A. Donato
Journal: Annals of Internal Medicine (2017)

Source Citation Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016. [Epub ahead of print]. 27633186
Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia
Authors: E J Murphy, D S Neuberg, L Z Rassenti, G Hayes, R Redd, C Emson, K Li, J R Brown, W G Wierda, S Turner, A W Greaves, C S Zent, J C Byrd, C McConnel, J Barrientos, N Kay, M K Hellerstein, N Chiorazzi, T J Kipps, K R Rai
Journal: Leukemia (2017)
Dynamin-Related Protein-1 Controls Fusion Pore Dynamics During Platelet Granule Secretion and Thrombus Formation In Vivo
Authors: Robert C. Flaumenhaft, Secil Koseoglu, James R. Dilks, Christian G. Peters, Nathalie A. Fadel, Reema Jasuja, Christy L. Haynes
Journal: Blood (2011)
Blood pressure–associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding
Authors: Xue Bai, Kevin D. Mangum, Rachel A. Dee, George A. Stouffer, Craig R. Lee, Akinyemi Oni-Orisan, Cam Patterson, Jonathan C. Schisler, Anthony J. Viera, Joan M. Taylor, Christopher P. Mack
Journal: Journal of Clinical Investigation (2017)

We recently demonstrated that selective expression of the Rho GTPase-activating protein ARHGAP42 in smooth muscle cells (SMCs) controls blood pressure by inhibiting RhoA-dependent contractility, providing a mechanism for the blood pressure–associated locus within the ARHGAP42 gene. The goals of the current study were to identify polymorphisms that affect ARHGAP42 expression and to better assess ARHGAP42’s role in the development of hypertension. Using DNase I hypersensitivity methods and ENCODE data, we have identified a regulatory element encompassing the ARHGAP42 SNP rs604723 that exhibits strong SMC-selective, allele-specific activity. Importantly, CRISPR/Cas9–mediated deletion of this element in cultured human SMCs markedly reduced endogenous ARHGAP42 expression. DNA binding and transcription assays demonstrated that the minor T allele variation at rs604723 increased the activity of this fragment by promoting serum response transcription factor binding to a cryptic cis-element. ARHGAP42 expression was increased by cell stretch and sphingosine 1-phosphate in a RhoA-dependent manner, and deletion of ARHGAP42 enhanced the progression of hypertension in mice treated with DOCA-salt. Our analysis of a well-characterized cohort of untreated borderline hypertensive patients suggested that ARHGAP42 genotype has important implications in regard to hypertension risk. Taken together, our data add insight into the genetic mechanisms that control blood pressure and provide a potential target for individualized antihypertensive therapies.
Unraveling the regulation of a putative cancer stem cell-like population in esophageal cancer.
Authors: Da Wang, Justin Smit, Roland Chiu, John Theodorus Plukker, Robert P. Coppes
Journal: Journal of Clinical Oncology (2015)

77 Background: Despite advances in the treatment of esophageal cancer (EC), most patients face poor outcome. Mounting evidence indicates that cancer stem cells (CSCs) might contribute to the poor prospects. Whereas most cancer cells are sensitive to chemo- and/or radiotherapy (CRT), CSCs are generally resistant and ultimately have the potential to generate a new tumor. Mechanisms regulating EC CSCs are poorly understood and need to be elucidated. Previously, we identified a putative CSC-like population (CD24-/CD44+) in EC cell lines and in esophageal adenocarcinoma (EAC). Here we show that the Hedgehog signaling pathway may regulate CSC-like populations in EC. Methods: To identify up-regulated CSC related genes, qPCR arrays were performed on CD24-/CD44+ OE21 esophageal squamous cell carcinoma (ESCC) and OE33 (EAC). CD24-/CD44+ was compared to CD24+/CD44+ and solid tumors generated from the same cell lines obtained from xenografts. Immunohistochemical (IHC) staining from tumor material of microscopical residual disease (mRD) patients after CRT was compared to surgery alone patients (S). Results: From a panel of 84 CSC related genes, Ptch1 was found to be up-regulated in the OE21 CD24-/CD44+ putative CSC-like population when compared to CD24+/CD44+ population and the solid tumor (2.5 and 3.7 fold, respectively). Furthermore, in OE33 this up-regulation was 1.4 and 1.7 fold. From 6 preselected candidate CRT response markers, CD44 and Sonic Hedgehog (SHH) expression was 55% (p&lt;0.05) and 64% (P&lt;0.005) enhanced in mRD compared to the S group in IHC material. Moreover, SHH expression showed a positive correlation coefficient of 0.551 (P&lt;0.005) with CD44 and 0.512 (P&lt;0.05) with Excision Repair Cross-Complementation group 1 (ERCC1, a nucleotide excision repair gene) in mRD tissue. Conclusions: These findings indicate that the Hedgehog pathway might be involved in regulating EC CSC-like properties. Although requiring further research, an exciting prospect would be the modulation of the Hedgehog pathway in combating CSC-like populations and the potential predictive value of SHH expression on treatment outcome.
Cytoreductive radical nephrectomy (cRN) and level II-IV infereior vena cava (IVC) thrombectomy for metastatic renal cell carcinoma (mRCC).
Authors: Joseph C. Klink, Karin E. Westesson, Brian I. Rini, John C. Rabets, Steven C. Campbell, Islam Ghoneim, Andrew J. Stephenson, Venkatesh Krishnamurthi
Journal: Journal of Clinical Oncology (2012)

382 Background: cRN for mRCC is associated with a modest improvement in survival when combined with cytokine therapy in patients with good performance status. A level II-IV IVC thrombus renders cRN technically challenging with increased risks of perioperative morbidity and mortality. The outcome of these patients relative to the overall cRN population is poorly defined. Methods: Clinical information and follow-up data were obtained from an institutional retrospective data base for patients who underwent cRN and IVC thrombectomy between 1990–2011.The operative outcomes, complications, and cancer outcomes were compared. Results: cRN was performed on 56 patients with mRCC and level II (N =19), III (N =25) or IV (N =12) IVC thrombus. Age ranged from 23 to 84 years old and 36 (64%) were male. Predominant sites of metastases were: lung, 22 (39%); liver 3 (5%); mediastinum 3 (5%); multiple sites 17 (30%). Local clinical stage was T3a in 2 (3.6%), T3b in 38 (68%), T3c in 12 (21%), and T4 in 4 (7%). Twenty (36%) patients were clinical N1. Median tumor size was 10.2 cm (range, 1.4–21). Histologic classification was clear cell in 40 (71%), papillary in 4 (7%), and unclassified in 12 (21%). Intraoperatively, 2 patients had embolization of thrombus. Postoperatively, Clavien grade 3–5 complications occurred in 3 (5%) patients, including two (3.6%) mortalities. Follow-up information was available for 49 patients and the median follow-up was 13 months (IQR: 6–33). Of these patients, 31 (63%) received postoperative systemic therapy with cytokines (14), targeted agents (16), or both (1). The overall median survival was 13 months (95% CI: 10–16), and was similar before (median 12 months) and after (median 13 months) the introduction of targeted therapy. Conclusions: Among patients with mRCC with level II–IV IVC thrombus managed at a high-volume kidney center, cRN and IVC thrombectomy is associated with acceptable perioperative morbidity and mortality. The median survival of patients in our cohort is similar to the overall population of patients managed with cRN and cytokine therapy though less than those managed with cRN and targeted therapy based on data from published randomized trials.
Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).
Authors: Hui Yang, Carlos E. Bueso-Ramos, Sherry A. Pierce, Yue Wei, Zhihong Fang, Martin Nguyen, Michael Fernadez, Marylou Cardenas-Turanzas, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2012)
A High Density Polymorphism Analysis of Factors Correlated with Neurotoxicity to Bortezomib in Patients with Multiple Myeloma.
Authors: Stephane Minvielle, Céline Keime, Florence Magrangeas, Julie Vendrell, Wilfried Gouraud, Sergio Rodrigues de Morais, Stephanie Montesinos, Charles Dumontet, H. Avet-Loiseau
Journal: Blood (2009)
Pooled Data Analysis of Acute Myeloid Leukemia Patients &amp;lt;= 60 Years with Trisomy 8 Treated within the Studies of the German Acute Myeloid Leukemia Intergroup.
Authors: Markus Andreas Schaich, Silke Soucek, Hartmut Döhner, Gerhard Ehninger, Arnold Ganser, Gerhard Heil, Rainer Krahl, Jürgen Krauter, Dietger W. Niederwieser, Christina Sauerland, Thomas Büchner, Richard F. Schlenk
Journal: Blood (2005)
Clinical Relevance of IDH1 and IDH2 Mutations and Single Nucleotide Polymorphism (SNP) rs11554137 in Patients with Acute Myeloid Leukemia Treated with Stem Cell Transplant in First Complete Remission
Authors: Hala Abalkhail, Naeem A. Chaudhri, Claudia Ulrike Walter, Hazzaa Al Zahrani, Randa Nounou, Ola Altombakty, Fahed Almhareb, Said Mohamed, Walid Rasheed, Fahad Alsharif, Mahmoud Aljurf, Maher Albitar
Journal: Blood (2011)
Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers
Authors: Min Kyoung Kim, Chang-Ki Min, Myung Soo Hyun, Kihyun Kim, Sung-Soo Yoon, Jin Seok Kim, Hyeon Seok Eom, Cheolwon Suh, Hye Jin Kang, Jeong-A Kim, Yeung-Chul Mun, Ho-Jin Shin, Deog-Yeon Jo, Chul Won Choi, Joon Ho Moon, Yang Soo Kim, Deok-Hwan Yang, Sung Hwa Bae, Gyeong-Won Lee, Jung Hye Kwon, Kyoung Ha Kim, Hwi-Joong Yoon, Chul Soo Kim, Joon Seong Park, Jae Hoon Lee
Journal: Blood (2011)
Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival
Authors: Cornelia Becker, Rainer Krahl, Antje Schulze, Georg Maschmeyer, Christian Junghanß, Astrid Franke, Norma Peter, Mathias Haenel, Ulrich Wedding, Hans-Heinrich Wolf, Detlev Haehling, Johannes Meran, Gottfried Doelken, Dietrich Kaempfe, Erika Kettner, Norbert Grobe, Axel Florschuetz, Ute Kreibich, Veronika Schirmer, Thomas Ittel, Mathias Schulze, Renate Huhn, Ernst Zschuppe, Bernd Opitz, Michael Assmann, Dirk Hasenclever, Wolfram Poenisch, Werner Helbig, Dietger W. Niederwieser
Journal: Blood (2008)
Multiplex Fluorescence In Situ Hybridization (M-FISH) in the Detection of Complex Karyotypic Abnormalities of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Authors: Jianyong Li, Jinlan Pan, Bing Xiao, Li Ma, Hairong Qiu, Li Li, Wei Xu, Yongquan Xue, Changgeng Ruan
Journal: Blood (2005)
Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells
Authors: Kapil Bhalla, Warren Fiskus, Stephen K. Horrigan, Sunil Abhyankar, Joseph McGuirk, Sunil Sharma
Journal: Blood (2012)
Long-term durable oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Authors: Sarah P. Psutka, Francis J. McGovern, Peter Mueller, W. Scott McDougal, Debra Gervais, Adam S. Feldman
Journal: Journal of Clinical Oncology (2012)

384 Background: Long-term oncologic outcomes for radiofrequency ablation (RFA) of renal cell carcinoma (RCC) are limited. The objective of this study was to assess the long-term oncological efficacy of RFA for treatment of renal cell carcinoma. Methods: Between 1998 and 2008, 311 biopsy-proven RCC were treated with RFA in 274 patients. Exclusion criteria included history of prior RCC or known metastatic RCC at time of RFA (n=92). 26 patients were lost to follow-up prior to their 6-month imaging study. We retrospectively reviewed the long-term oncologic outcomes for 193 patients. Mean follow-up was 4.6 yrs (range 1–12, SD 2.3). Results: Median age was 71 years (IQR: 63 –79 years). Median Charlson Score was 5.46 (IQR: 5–6). Median size of tumor treated was 3 cm (IQR: 2–3.9 cm, range 1–7.1cm) and 64 of these tumors (33%) were endophytic. Tumor breakdown by stage was T1a: n=153 (79%), T1b: n=37 (19%), and T2: n=3 (2%). Initial treatment success rate was 89%. There were 6 local recurrences (3%) in 4 patients with T1b disease and 2 patients with T2 disease with an average time-to-recurrence of 2.9 years (SD 0.7). 95% of patients with T1a RCC were disease free at last follow-up, in comparison to 81% of those with T1b and 33% of those with T2 disease (p=0.008). At last follow-up 178 (92%) patients were disease-free. 16 (8.2%) developed metastatic disease and 4 patients (2%) died of RCC. Mean disease-free survival was 4.3 years (SD 2.4). Conclusions: In patients who are poor surgical candidates, RFA results in durable local control and a low risk of disease recurrence in T1 RCC. Higher stage, however, correlates with a decreased disease free survival and alternate treatments should be considered when counseling these patients.
Physiological parameters of seed vigour in ex situ stored sorghum germplasm
Authors: Wodaje Addis Tegegne
Journal: Journal of Clinical Oncology (2015)

The concentrations of nine heavy metals (Fe, Zn, Cu, Mn, Ni, Co, Cr, Pb and Cd) in four varieties of cereals (wheat, barley, sorghum and maize) purchased from Ambo market, Ethiopia were determined using Atomic Absorption Spectrophotometers (AAS). Dry ashing method was used to destroy the organic matter to determine the content of nine heavy metals. The results showed that the concentrations of heavy metals in mg kg−1 dry weight were in the range of: Cu (0.13 - 1.72), Fe (0.40 - 36.45), Zn (0.66 - 8.54), Mn (0.42 - 7.67), Co (0.14 - 0.45), Ni (ND - 0.43), Cr (0.29 - 0.95) and Pb (non-detectable - 0.08), respectively. Cadmium was not detected in any of the cereal samples. In addition, the mean concentrations of heavy metals in cereals purchased from Ambo market decreases in the following order: Fe > Zn > Mn > Cu > Cr > Co > Ni > Pb > Cd. The trace metals Fe, Zn and Mn were higher than the entire heavy metals in the samples investigated while Cd and Pb were in minor quantities and hence the cereals were free from toxic heavy metals. The author concluded that the levels of heavy metals determined in the analyzed cereal samples were found below the permissible limits set by FAO/ WHO; hence they are safe for human consumption and can be considered as good sources of essential trace metals to the individuals.

	 

	Key words: Cereals, heavy metals, atomic absorption spectrophotometers (AAS).
Clinical Features and Outcome of Patients with Acute Myeloid Leukaemia (AML) and Central Nervous System Involvement at the Time of Diagnosis and during the Course of AML - Retrospective, Multicentre Study of the Polish Adult Leukemia Group (PALG)
Authors: Elzbieta Patkowska, Joanna Gora Tybor, Ewa Lech Maranda, Maciej Kazmierczak, Marta Baranska, Andrzej Szczepaniak, Monika Paluszewska, Wieslaw W Jedrzejczak, Renata Guzicka Kazmierczak, Wanda Knopinska Posluszny, Olga Grzybowska Izydorczyk, Jaroslaw Piszcz, Izabela Deren Wagemann, Krzysztof Warzocha
Journal: Blood (2015)